Related Experiment Video
Updated: Jul 23, 2026

The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
Triple therapy for atrial fibrillation and percutaneous coronary intervention: a contemporary review
Willem J M Dewilde1, Paul W A Janssen2, Freek W A Verheugt3
1Department of Cardiology, Amphia Hospital, Breda, the Netherlands.
Insights
For patients on chronic oral anticoagulation undergoing stenting, triple therapy with aspirin and clopidogrel increases bleeding risk. Evidence suggests aspirin may not be necessary, challenging current guidelines for preventing thromboembolic events.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Chronic oral anticoagulation is standard for mechanical heart valves and atrial fibrillation (CHA2DS2-VASc score ≥1).
- Percutaneous coronary intervention with stenting in these patients necessitates dual antiplatelet therapy alongside anticoagulation.
- Historically, triple therapy (VKA, aspirin, clopidogrel) was recommended, but major bleeding is a significant concern.
Purpose of the Study:
- To evaluate the necessity of aspirin in triple therapy for patients on oral anticoagulation undergoing stenting.
- To determine the optimal balance between preventing thromboembolic events and minimizing bleeding risk in this patient population.
Main Methods:
- Review of recent studies, including a prospective randomized trial, investigating triple therapy regimens.
- Analysis of evidence regarding the efficacy and safety of adding aspirin to vitamin K antagonists and clopidogrel.
Main Results:
- The evidence supporting the addition of aspirin to vitamin K antagonists and clopidogrel appears weakened.
- Major bleeding is a recognized significant risk associated with traditional triple therapy.
Conclusions:
- Re-evaluation of aspirin's role in triple therapy for anticoagulated patients undergoing stenting is warranted.
- Finding an optimal antithrombotic strategy to prevent stent thrombosis and stroke without excessive bleeding remains a critical clinical challenge.
Abstract:
Chronic oral anticoagulant therapy is recommended (class I) in patients with mechanical heart valves and in patients with atrial fibrillation with a CHA2DS2-VASc (Congestive heart failure, Hypertension, Age ≥75 years, Diabetes mellitus, prior Stroke or transient ischemic attack or thromboembolism, Vascular disease, Age 65 to 74 years, Sex category) score ≥1. When these patients undergo percutaneous coronary intervention with stenting, treatment with aspirin and a P2Y12 receptor inhibitor also becomes indicated. Before 2014, guidelines recommended the use of triple therapy (vitamin K antagonists, aspirin, and clopidogrel) for these patients. However, major bleeding is increasingly recognized as the Achilles' heel of the triple therapy regimen. Lately, various studies have investigated this topic, including a prospective randomized trial, and the evidence for adding aspirin to the regimen of vitamin K antagonists and clopidogrel seems to be weakened. In this group of patients, the challenge is finding the optimal equilibrium to prevent thromboembolic events, such as stent thrombosis and thromboembolic stroke, without increasing bleeding risk.
More Related Videos
Related Concept Videos
Pericarditis III: Medical Management
Coronary Artery Disease V: Interprofessional Care
Acute Coronary Syndrome III: Diagnostic Studies
Acute Coronary Syndrome IV: Interprofessional Care
Atherosclerosis III: Management
Peripheral Artery Disease III: Interprofessional Care

